IMRX vs STE · $124.2M cap vs P/E 25, rev $5.46B
Immuneering Corp (IMRX) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
IMRX currently screens at market cap $124.2M. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the IMRX and STE stock pages for the full models.
Not investment advice.